论文部分内容阅读
目的探讨奈达铂与洛铂同步放化疗治疗局部晚期宫颈癌的临床疗效及不良反应。方法选取2015年1月至2016年1月间陕西省扶风县人民医院收治的80例局部晚期宫颈癌患者,根据患者入院时间顺序交替分为观察组与对照组,每组40例。观察组患者采用奈达铂3周方案同步放化疗,对照组患者采用洛铂3周方案同步放化疗,比较两组患者的疗效及不良反应。结果观察组患者临床总有效率为85.0%,明显高于对照组患者的62.5%,两组比较,差异有统计学意义(P<0.05)。观察组患者治疗后,肿瘤最大直径为(1.71±0.87)cm,明显小于治疗前的(4.75±1.59)cm,对照组患者治疗后肿瘤最大直径为(2.31±1.09)cm,明显小于治疗前的(4.72±1.54)cm,差异均有统计学意义(均P<0.05)。且观察组患者治疗后肿瘤最大直径小于对照组患者,组间比较,差异有统计学意义(P<0.05)。观察组患者不良反应总发生率为47.5%,低于对照组患者的82.5%,组间比较,差异有统计学意义(P<0.05)。结论奈达铂同步放化疗治疗局部晚期宫颈癌患者的临床疗效好,不良反应较轻,患者耐受性高,值得临床推广。
Objective To investigate the clinical efficacy and side effects of concurrent nedaplatin and lobaplatin in the treatment of locally advanced cervical cancer. Methods Eighty patients with locally advanced cervical cancer who were admitted to Fufeng County People’s Hospital of Shaanxi Province between January 2015 and January 2016 were randomly divided into observation group and control group according to the order of admission, with 40 cases in each group. Patients in the observation group received nedaplatin 3-week regimen concurrent chemoradiotherapy, while patients in the control group received concurrent chemoradiotherapy with lobaplatin 3-week regimen. The curative effect and adverse reactions of the two groups were compared. Results The total clinical effective rate in the observation group was 85.0%, which was significantly higher than that in the control group (62.5%). There was significant difference between the two groups (P <0.05). After treatment, the maximum diameter of tumor in observation group was (1.71 ± 0.87) cm, which was significantly lower than that before treatment (4.75 ± 1.59) cm. The maximum diameter of tumor in control group was (2.31 ± 1.09) cm, (4.72 ± 1.54) cm, the differences were statistically significant (all P <0.05). The maximum diameter of tumor in the observation group was smaller than that in the control group. There was significant difference between the two groups (P <0.05). The total incidence of adverse reactions in observation group was 47.5%, which was lower than that in control group (82.5%). There was significant difference between groups (P <0.05). Conclusion Nedaplatin concurrent chemoradiotherapy for locally advanced cervical cancer patients with good clinical efficacy, less adverse reactions, patients with high tolerance, it is worth clinical promotion.